Amyloidosis pp 545-557 | Cite as

Primary Systemic Amyloidosis (AL): Comparison of Melphalan-Prednisone vs. Colchicine Treatment in 101 Cases

  • Robert A. Kyle
  • Philip R. Greipp
  • John P. Garton
  • Morie A. Gertz


One hundred one patients with primary amyloidosis (AL) were stratified in four groups on the basis of their major clinical features: 1) Nephrotic syndrome or renal insufficiency; 2) congestive heart failure; 3) peripheral neuropathy; and 4) other. The patients were randomized to 1) melphalan (0.15 mg/kg daily) and prednisone (0.8 mg/kg daily) for 7 days every 6 weeks, or 2) colchicine (0.6 mg twice a day). Forty-nine patients were randomized to melphalan-prednisone (M-P) therapy, while 52 were to receive colchicine (C). No important differences were found between the two groups in the history or the initial physical examination and laboratory findings. If there was progressive disease or lack of benefit from therapy, either M-P or C was added to the original therapeutic regimen. Twenty-one of the 40 patients with the nephrotic syndrome who received M-P had >50% reduction in urinary protein. Four patients died of acute nonlymphocytic leukemia. The median survival was 25 months for the M-P group and 18 months for the C group (P = 0.23). When survival was calculated from the onset of randomization to death or progression of disease, the median survival was 16 months for the M-P group and 6 months for the C group (P = 0.0001).


Congestive Heart Failure Nephrotic Syndrome Peripheral Neuropathy Familial Mediterranean Fever Pernicious Anemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. A. Kyle and E. D. Bayrd, Medicine, Baltimore, 54:271 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    R. A. Kyle and P. R. Greipp, Mayo Clin. Proc., 58:665 (1983).PubMedGoogle Scholar
  3. 3.
    E. F. Osserman, et al., Semin. Hematol., 1:3 (1964).PubMedGoogle Scholar
  4. 4.
    G. G. Glenner, et al., Science, 172:1150 (1971).PubMedCrossRefGoogle Scholar
  5. 5.
    W. D. Terry, et al., J. Clin. Invest., 52:1276 (1973).PubMedCrossRefGoogle Scholar
  6. 6.
    A. S. Cohen and O. Wegelius, Arthritis Rheum., 23:644 (1980).PubMedCrossRefGoogle Scholar
  7. 7.
    R. A. Kyle and E. D. Bayrd, Arch. Intern. Med., 107: 344 (1961).PubMedGoogle Scholar
  8. 8.
    G. Costa, et al., Am. J. Med., 54:589 (1973).CrossRefGoogle Scholar
  9. 9.
    H. J. Cohen, et al., Ann. Intern. Med., 82:466 (1975).PubMedGoogle Scholar
  10. 10.
    N. F. Jones, et al., Lancet, 2:616 (1972).PubMedCrossRefGoogle Scholar
  11. 11.
    M. K. Hörne, III, Ann. Intern. Med., 83:281 (1975).PubMedGoogle Scholar
  12. 12.
    R. S. Schwartz, et al., Arch. Intern. Med., 139:1144 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    J. N. Buxbaum, et al., Am. J. Med., 67:867 (1979).PubMedCrossRefGoogle Scholar
  14. 14.
    R. A. Kyle, et al, Blood, 44:333 (1974).PubMedGoogle Scholar
  15. 15.
    R. A. Kyle, et al., Arch. Intern. Med., 142:1445 (1982).PubMedCrossRefGoogle Scholar
  16. 16.
    A. D. Mehta, Br. J. Clin. Pract., 32:358 (1978).PubMedGoogle Scholar
  17. 17.
    K. Bradstock, et al., Aust. NZ. J. Med., 8:176 (1978).CrossRefGoogle Scholar
  18. 18.
    J. Corkery, et al., Lancet, 2:425 (1978).PubMedCrossRefGoogle Scholar
  19. 19.
    R. A. Kyle, P. R. Greipp, Blood, 52:818 (1978).PubMedGoogle Scholar
  20. 20.
    E. Sohar, et al., Am. J. Med., 43:227 (1967).PubMedCrossRefGoogle Scholar
  21. 21.
    S. E. Goldfinger, New Engl. J. Med., 287:1302 (1972).PubMedGoogle Scholar
  22. 22.
    H. A. Reimann, JAMA, 231:64 (1975).PubMedCrossRefGoogle Scholar
  23. 23.
    T. Shirahama and A. S. Cohen, J. Exp. Med., 140:1102 (1974).PubMedCrossRefGoogle Scholar
  24. 24.
    I. Kedar (Keizman), et al., Isr. J. Med. Sci., 10:787 (1974).PubMedGoogle Scholar
  25. 25.
    D. Zemer, et al., New Engl. J. Med., 294:170 (1976).PubMedCrossRefGoogle Scholar
  26. 26.
    P. Nimoityn, et al., Br. Med. J., 2:284 (1976).PubMedCrossRefGoogle Scholar
  27. 27.
    I. Melamed, et al., Clin. Exp. Immunol., 53:659 (1983).PubMedGoogle Scholar
  28. 28.
    M. J. Seiinger, et al., Nature, 285:498 (1980).CrossRefGoogle Scholar
  29. 29.
    E. Tatsuta, et al., Arthritis Rheum., 27:349 (1984).PubMedCrossRefGoogle Scholar
  30. 30.
    A. Rubinow, et al., Arthritis Rheum., 24:S124 (1981).CrossRefGoogle Scholar
  31. 31.
    J. Michael and N. F. Jones, Br. Med. J., 1:1592 (1978).PubMedCrossRefGoogle Scholar
  32. 32.
    T. Shirahama and A. S. Cohen, Am. J. Pathol., 99:539 (1980).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Robert A. Kyle
    • 1
  • Philip R. Greipp
    • 1
  • John P. Garton
    • 1
  • Morie A. Gertz
    • 1
  1. 1.Division of Hematology and Internal MedicineMayo Clinic and Mayo FoundationRochesterUSA

Personalised recommendations